Mark Baldry - 01 Nov 2023 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Commercial Officer
Issuer ticker: XFOR
Reported as of: 01 Nov 2023
Net transaction value: -$7,488
SEC form: 4
Accepted by SEC: 03 Nov 2023, 16:39:45 UTC
Prior SEC filing: 02 Nov 2023
Next SEC filing: 16 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Mark Baldry filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 03 Nov 2023.

Key facts

This page summarizes Mark Baldry's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Nov 2023, 16:39.

Change

Previous filing in this sequence was filed on 02 Nov 2023.
Current net transaction value: -$7,488.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Sale

Transaction value: $7,488
Shares: -10,257
Change %: -29%
Price: $0.7300
Shares after: 24,690
Date: 01 Nov 2023
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

Footnote F2

Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.687 to $0.7927, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.